Status: Not yet recruiting
VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML
The purpose of this study is to explore the efficacy and safety of venetoclax combined with azacitidine（VA) induction followed by bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hypoplastic and secondary acute myeloid leukemia (AML).
Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital of Soochow UniversityUpdated: Jun 9, 2026Locations: 1
Eligibility criteria
Age ≥18 years. [+7]
Prior treatment for AML, except non-cytotoxic therapy given to stabilize disease... [+18]